NUVB
NYSE HealthcareNuvation Bio Inc. Class A Common Stock
Biotechnology
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
๐ Market Data
| Price | $5.64 |
|---|---|
| Volume | 4,009,767 |
| Market Cap | 1.96B |
| Beta | 1.530 |
| RSI (14-Day) | 46.0 |
| 200-Day MA | $5.55 |
| 50-Day MA | $5.17 |
| 52-Week High | $9.75 |
| 52-Week Low | $2.18 |
| Forward P/E | -94.00 |
| Price / Book | 6.14 |
๐ฏ Investment Strategy Scores
NUVB scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (83/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NUVB in your text
Paste any article, transcript, or post โ the tool will extract NUVB and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.